11/26
02:15 pm
rlyb
Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
01:38 pm
rlyb
Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Rallybio (NASDAQ:RLYB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:00 am
rlyb
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
10/12
01:08 am
rlyb
Low
Report
10/4
03:07 am
rlyb
Low
Report
9/27
10:17 am
rlyb
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)? [Yahoo! Finance]
Low
Report
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)? [Yahoo! Finance]
9/25
08:17 am
rlyb
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study [Yahoo! Finance]
Medium
Report
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study [Yahoo! Finance]
9/25
08:00 am
rlyb
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Medium
Report
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study